Patents by Inventor Sabine Eming

Sabine Eming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteolysis Resistant Active VEGF
    Publication number: 20120258915
    Abstract: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 11, 2012
    Applicant: BAYER INNOVATION GMBH
    Inventors: Sabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer
  • Use of proteolysis resistant active VEGF
    Patent number: 8168590
    Abstract: The invention relates to vascular endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: May 1, 2012
    Assignee: Bayer Innovation GmbH
    Inventors: Sabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer
  • PROTEOLYSIS RESISTANT ACTIVE VEGF
    Publication number: 20110009316
    Abstract: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
    Type: Application
    Filed: January 7, 2009
    Publication date: January 13, 2011
    Applicant: BAYER INNOVATION GMBH
    Inventors: Sabine EMING, Thomas KRIEG, Stephan SOLLBERG, Gereon LAUER
  • Proteolysis resistant active VEGF
    Patent number: 7491696
    Abstract: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: February 17, 2009
    Assignee: Bayer Innovation GmbH
    Inventors: Sabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer
  • Proteolysis resistant active vegf
    Publication number: 20060148687
    Abstract: The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.
    Type: Application
    Filed: March 6, 2003
    Publication date: July 6, 2006
    Inventors: Sabine Eming, Thomas Krieg, Stephan Sollberg, Gereon Lauer